U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
While having a definite cure for cancer is still in the works, the technological and medical advancements of today brought on some progress in that aspect. A report reveals a breakthrough made by scientists on the treatment of HER2-positive breast cancer.
CNN reports that a group of scientists were able to develop two new drugs for HER2-positive breast cancer treatment. A study in the New England Journal of Medicine revealed that scientists found that a drug called tucatinib, when combined with other drugs in the chemotherapy routine trastuzumab and capecitabine, can potentially improve survival within adults who are suffering from HER2-positive breast cancer, or the type of breast cancer that is high on a protein called HER2.
Another study in the same medical journal revealed that another drug conjugate, referred to as trastuzumab deruxtecan, also significantly reduced the tumor within HER2-positive breast cancer patients. Dr. Eric Winer of Harvard Medical School and the Dana-Farber Breast Cancer Institute expressed his happiness at the progress made upon the development of the drugs. “What’s so exciting is that we have developed multiple new drugs for HER2-positive breast cancer, we have new drugs for all subtypes of breast cancer, but the changes are most dramatic in the setting of HER2-positive breast cancer,” said Winer.
He added that because of the progress they made and will continue to make, breast cancer treatment can be configured to suit every kind of patient. “It is no longer one size fits all.”
Meanwhile, WebMD reveals that higher breast tissue density may increase a person’s chances of developing breast cancer. Many medical facilities in the United States are being urged to inform the women who undergo mammograms if they have high breast density tissue.
However, a new study that was conducted on this subject reveals that this may not be as helpful to women. While the objective of informing women if they have dense breast tissue is to be able to talk about their personal risk of developing breast cancer, later on, the study found that not many women actually understood what this would mean for them. Therefore, the researchers concluded that doctors or health care providers need to word their explanations properly, so it is understood and, at the same time, reduce other consequences like having anxiety regarding this.
